HRP20200351T1 - Cikloalkinski derivati saharida - Google Patents

Cikloalkinski derivati saharida Download PDF

Info

Publication number
HRP20200351T1
HRP20200351T1 HRP20200351TT HRP20200351T HRP20200351T1 HR P20200351 T1 HRP20200351 T1 HR P20200351T1 HR P20200351T T HRP20200351T T HR P20200351TT HR P20200351 T HRP20200351 T HR P20200351T HR P20200351 T1 HRP20200351 T1 HR P20200351T1
Authority
HR
Croatia
Prior art keywords
saccharide
conjugate
group
azide
spacer
Prior art date
Application number
HRP20200351TT
Other languages
English (en)
Croatian (hr)
Inventor
Roberto ADAMO
Francesco Berti
Qi-Ying Hu
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20200351T1 publication Critical patent/HRP20200351T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HRP20200351TT 2013-01-15 2014-01-13 Cikloalkinski derivati saharida HRP20200351T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1300707.5A GB201300707D0 (en) 2013-01-15 2013-01-15 Compounds and processes
PCT/EP2014/050483 WO2014111344A1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides
EP14700602.7A EP2945641B1 (en) 2013-01-15 2014-01-13 Cycloalkyne derivatized saccharides

Publications (1)

Publication Number Publication Date
HRP20200351T1 true HRP20200351T1 (hr) 2020-06-12

Family

ID=47758014

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200351TT HRP20200351T1 (hr) 2013-01-15 2014-01-13 Cikloalkinski derivati saharida

Country Status (16)

Country Link
US (2) US11135300B2 (enExample)
EP (1) EP2945641B1 (enExample)
JP (3) JP6719209B2 (enExample)
CN (1) CN105377282B (enExample)
BR (1) BR112015016817B1 (enExample)
CA (1) CA2897348C (enExample)
CY (1) CY1122822T1 (enExample)
DK (1) DK2945641T3 (enExample)
ES (1) ES2774729T3 (enExample)
GB (1) GB201300707D0 (enExample)
HR (1) HRP20200351T1 (enExample)
LT (1) LT2945641T (enExample)
PL (1) PL2945641T3 (enExample)
PT (1) PT2945641T (enExample)
SI (1) SI2945641T1 (enExample)
WO (1) WO2014111344A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes
CN108697741B (zh) * 2016-03-04 2023-04-14 悠绿那股份有限公司 抗病毒剂及抗病毒用食品
EP4588521A3 (en) 2016-12-30 2025-10-22 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7295571B2 (ja) * 2018-02-05 2023-06-21 国立大学法人 宮崎大学 細胞標識剤及び細胞標識キット
EP3808783A4 (en) 2018-06-14 2022-03-16 Mochida Pharmaceutical Co., Ltd. Novel crosslinked alginic acid
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
KR20230052958A (ko) 2020-08-19 2023-04-20 박사이트, 인코포레이티드 운반-단백질 폴리삭카라이드 접합 방법
KR20230175284A (ko) * 2021-05-28 2023-12-29 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
JP2024075506A (ja) * 2022-11-22 2024-06-03 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1490409E (pt) 2002-03-26 2009-04-03 Novartis Vaccines & Diagnostic Sacáridos modificados possuindo uma estabilidade melhorada em água
MX2007005202A (es) * 2004-11-01 2007-07-09 Brigham & Womens Hospital Polisacaridos de estreptococo modificados y usos de los mismos.
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CN101925366B (zh) * 2007-11-21 2015-02-04 乔治亚大学研究基金公司 炔烃以及炔烃与1,3-偶极-官能化合物反应的方法
ITVI20090234A1 (it) * 2009-09-25 2011-03-26 Termotecniche Fraccaro S R L Off Dispositivo per il riscaldamento di ambienti ad alta efficienza energetica, nonche' sistema riscaldante comprendente tale dispositivo
EP2515914A4 (en) 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
US8859629B2 (en) * 2010-04-27 2014-10-14 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
WO2012017701A1 (ja) * 2010-08-05 2012-02-09 株式会社ミュージックゲート いびき防止マスク
GB201101665D0 (en) * 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US9315468B2 (en) 2010-09-27 2016-04-19 University Of Georgia Research Foundation, Inc. Methods including latent 1,3-dipole-functional compounds and materials prepared thereby
US20120208722A1 (en) * 2010-10-19 2012-08-16 Richard Dluhy Surface enhanced raman spectroscopy platforms and methods
WO2012177701A2 (en) * 2011-06-20 2012-12-27 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
HK1200190A1 (en) * 2011-12-01 2015-07-31 安吉奥开米公司 Targeted enzyme compounds and uses thereof
GB201300707D0 (en) * 2013-01-15 2013-02-27 Novartis Ag Compounds and processes

Also Published As

Publication number Publication date
BR112015016817A8 (pt) 2019-10-29
JP6719209B2 (ja) 2020-07-08
PL2945641T3 (pl) 2020-06-15
CA2897348C (en) 2022-09-27
GB201300707D0 (en) 2013-02-27
US20160166704A1 (en) 2016-06-16
JP2019073528A (ja) 2019-05-16
JP2020114839A (ja) 2020-07-30
EP2945641B1 (en) 2020-01-01
US11135300B2 (en) 2021-10-05
ES2774729T3 (es) 2020-07-22
LT2945641T (lt) 2020-02-25
US20210268116A1 (en) 2021-09-02
WO2014111344A1 (en) 2014-07-24
BR112015016817A2 (pt) 2017-07-11
EP2945641A1 (en) 2015-11-25
JP2016506905A (ja) 2016-03-07
CY1122822T1 (el) 2021-05-05
JP7036854B2 (ja) 2022-03-15
BR112015016817B1 (pt) 2020-11-10
CA2897348A1 (en) 2014-07-24
CN105377282A (zh) 2016-03-02
US12409231B2 (en) 2025-09-09
CN105377282B (zh) 2020-07-17
DK2945641T3 (da) 2020-03-09
PT2945641T (pt) 2020-03-26
SI2945641T1 (sl) 2020-03-31

Similar Documents

Publication Publication Date Title
HRP20200351T1 (hr) Cikloalkinski derivati saharida
JP2016506905A5 (enExample)
Still et al. Alkaloids from Microcos paniculata with cytotoxic and nicotinic receptor antagonistic activities
WO2018098269A3 (en) Peptide-containing linkers for antibody-drug conjugates
Pérez-Guerrero et al. A pharmacological study of Cecropia obtusifolia Bertol aqueous extract
MX2009013508A (es) Composicion plaguicida que comprende un derivado de estrigolactona y un compuesto insecticida.
UY31867A (es) Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
GT200400174A (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4
WO2017062271A3 (en) Antibody drug conjugate for anti-inflammatory applications
CO6450634A2 (es) Composiciones plaguicidas
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2015134464A3 (en) Targeted therapeutics
WO2015066053A8 (en) Targeted therapeutics
CY1113063T1 (el) Παραγωγα πουρινης για χρηση ως αγωνιστες των α2α υποδοχεων αδενοσινης
NO20080302L (no) Humane anti-B7RP1 noytraliserende antistoffer
EA201591425A1 (ru) Мультивалентные гликоконъюгатные вакцины
BR112014026526A2 (pt) composições pesticidas e processos relacionados às mesmas
WO2011094337A8 (en) Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
Fonseca-Berzal et al. Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles
MX389728B (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
JP2017505777A5 (enExample)
WO2007100385A3 (en) Macrocyclic depsipeptide antibody-drug conjugates and methods
FI2766364T3 (fi) Albumiinia sitovien entiteettien folaattikonjugaatit
EP2548552A3 (en) Titration package for 1-amino-alkylcylohexanes
CY1115926T1 (el) Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης